ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
Kameswari S Konduri, Ram Pattisapu, Jogi Pattisapu, Girija G Konduri, John Zwetchkenbaum, Monalisa Barman ¥ Adria Frazier, Brett L Hurst
doi:10.1101/2021.05.05.442779
Background: Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant. ProLung™-budesonide may offer anti-inflammatory and protective effects to the lung in COVID-19, yet it's effect on SARS-CoV-2 replication is unknown. Objective: To determine the efficacy of ProLung™-budesonide against SARS-CoV-2 infection in vitro, evaluate its ability to decrease inflammation, and airway hyperresponsiveness in an animal model of lung inflammation. Methods: SARS-CoV-2-infected Vero 76 cells were treated with ProLung™-budesonide ([0.03-100 µg/ml]) for 3 days, and virus yield in the supernatant was measured. Ovalbumin-sensitized C57BL/6 mice received aerosolized (a) ProLung™-budesonide weekly, (b) only budesonide, either daily or weekly, or (c) weekly empty ProLung™-carrier (without budesonide). All treatment groups were compared to sensitized untreated, or normal mice using histopathologic examination,
TABLES AND FIGURES
References
Düzgüneş, Pretzer, Simões, Slepushkin, Konopka et al., Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells, Mol Membr Biol,
doi:10.1080/096876899294832Gabizon, Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy, Front Immunol,
doi:10.3389/fimmu.2017.00416Gangadharam, Ashtekar, Flasher, Düzgüneş, Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically was not certified by peer review) is the author/funder, Antimicrob Agents Chemother
George, Barratt, Condliffe, Desai, Devaraj et al., Respiratory follow-up of patients with COVID-19 pneumonia, Thorax
Hafner, Corthésy, Merkle, Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant, Adv Drug Deliv Rev,
doi:10.1016/j.addr.2013.05.013He, Yao, Chen, Wang, Fang et al., The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients, Sci Rep,
doi:10.1038/s41598-021-81300-wJung, Nam, Park, Lee, Hong et al., Protective effect of phosphatidylcholine on lipopolysaccharide-induced acute inflammation in multiple organ injury, Korean J Physiol Pharmacol,
doi:10.4196/kjpp.2013.17.3.209Konduri, Nandedkar, Düzgünes, Suzara, Artwohl et al., Efficacy of liposomal budesonide in experimental asthma, J Allergy Clin Immunol,
doi:10.1067/mai.2003.104Konduri, Nandedkar, Rickaby, Düzgüneş, Gangadharam, The use of sterically stabilized liposomes to treat asthma, Methods Enzymol,
doi:10.1016/S0076-6879(05)91023-9Majumdar, Flasher, Friend, Nassos, Yajko et al., Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages, Antimicrob Agents Chemother,
doi:10.1128/aac.36.12.2808Mason, Dobbs, Synthesis of phosphatidylcholine and phosphatidylglycerol by alveolar type II cells in primary culture, J Biol Chem
Monteil, Kwon, Prado, Hagelkrüys, Wimmer et al., Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2, Cell,
doi:10.1016/j.cell.2020.04.004Morris, Bortolasci, Puri, Olive, Marx et al., The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach, Life Sci,
doi:10.1016/j.lfs.2020.118166Nguyen, Rajaram, Meyer, Schlesinger, Pulmonary surfactant protein A and surfactant lipids upregulate IRAK-M, a negative regulator of TLR-mediated inflammation in human macrophages, Am J Physiol Lung Cell Mol Physiol,
doi:10.1152/ajplung.00067.2012Reed, Muench, A Simple Method of Estimating Fifty Percent Endpoints, Am J Hyg
Schousboe, Wiese, Heiring, Verder, Poorisrisak et al., Assessment of pulmonary surfactant in COVID-19 patients, Crit Care,
doi:10.1186/s13054-020-03268-9Song, Tang, Yin, Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells, Biomaterials,
doi:10.1016/j.biomaterials.2018.09.017Wang, Xie, Zhao, Fei, Zhang et al., Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients, EBioMedicine,
doi:10.1016/j.ebiom.2020.102833Wiedermann, Lederer, Mayr, Sepp, Herold et al., Prospective observational study of antiphospholipid antibodies in acute lung injury and acute respiratory distress syndrome: comparison with catastrophic antiphospholipid syndrome, Lupus,
doi:10.1191/0961203303lu413oa
